

Application: 6603

ČESKÁ SPOLEČNOST PRO FARMAKOEKONOMIKU A HODNOCENÍ ZDRAVOTNICKÝCH TECHNOLOGIÍ

Started at: 2/3/2023 06:22 PM - Finalized at: 2/4/2023 07:23 PM

Page: Contact Information
Chapter Name ČESKÁ SPOLEČNOST PRO FARMAKOEKONOMIKU A HODNOCENÍ ZDRAVOTNICKÝCH TECHNOLOGIÍ
Chapter Name Czech Chapter
Region Europe
First and Last Name of who is preparing this report Jiri Klimes
Chapter Position Chapter President
Email Address klimes.jiri@gmail.com
Page: The Chapter Board
First and Last Name (as it appears in ISPOR profile) Jiri Klimes
Email Address (as it appears in ISPOR profile) klimes.jiri@gmail.com
First and Last Name (as it appears in ISPOR profile) Tomas Mlcoch

President-Elect email address

xtomas.mlcoch@gmail.com

First and Last Name (as it appears in ISPOR profile)

Tomas Dolezal

Email Address (as it appears in ISPOR profile)

dolezal@iheta.org

First and Last Name (as it appears in ISPOR profile)

Bálint Pasztor

Email Address (as it appears in ISPOR profile)

pasztorbalint90@gmail.com

First and Last Name (as it appears in ISPOR profile)

Tomas Mlcoch

Email Address (as it appears in ISPOR profile)

xtomas.mlcoch@gmail.com

First and Last Name (as it appears in ISPOR profile)

Milan Vocelka

Email Address (as it appears in ISPOR profile)

vocelka.milan@gmail.com

First and Last Name (as it appears in ISPOR profile)

Ales Kminek

Email Address (as it appears in ISPOR profile)

ales.kminek@gmail.com

When are elections held for the Chapter Board?

Every 2 years

Chapter Elections

September, 2021

Page: The Chapter Operations

Chapter's Official Mailing Address

Václavská 316/12
Praha Czech Rep. 12000 CZ

Chapter's Official Email Address

klimes.jiri@gmail.com

Chapter Constitution

No

Is the Chapter officially registered with regional authorities in your country, e.g., is the Chapter a stand-alone legal entity as of December 2022?

Yes

Please name the regional authorities.

Mestsky soud v Praze

Does the Chapter have a bank account?

Yes

Chapter Website

Yes

Please provide the URL

<https://farmakoekonomika.cz/> (<https://farmakoekonomika.cz/>)

What channels of communication did the Chapter use to stay in contact with members? (email blast, newsletter, social media, website)

Email, Newsletter, Social Media, Chapter Website

Chapter Social Media Handles

<https://www.linkedin.com/company/35672601/admin/>

What are the 3 major challenges the Chapter is facing at the end of 2022?

- Implementation of the new reimbursement law for drugs, particularly orphans
- Use of societal perspective and wider social benefit, in HE evaluation for orphans
- WTP threshold - to create new framework of WTP setting., as the current one represents the single value (45k EUR/ QALY), w/o respecting additional value of technology/ unmet need

How can the ISPOR organization (Staff, Board, Consortia/Networks, etc.) better support your Chapter?

1. sharing best practices and possibilities to discuss with EU chapters their practices and experiences for the current CZ topics of interest. pls. note - the research around WTP will be kindly shared with you, in order to get the feedback from selected EU chapters.
2. Generally, we would appreciate very much to be exposed more to countries like NL, DE, FR, UK, Nordics, either by having mutual collaboration with these chapters, being exposed to their newsletters, and having speakers from these countries on our congresses.

Please list how the Chapter promotes benefits of ISPOR membership among Chapter members in the region

via mails, LinkedIn, sharing newsletters, etc...

Page: The Chapter Membership

Please indicate the number of Regional Chapter members in 2022.

145

Please indicate the range of Regional Chapter Members in 2022.

Large Chapter (More than 100 Chapter Members)

How many of your chapter members are ISPOR members?

Between 10-24

Did the Chapter collect membership dues or fees from individuals for local chapter membership?

Yes

If yes, please provide the amount.

25 USD/ year; for students 8 USD/ year

With percentages, please indicate the chapter member composition by work environment

Academia

5

Government/HTA Agency

10

Industry - Pharmaceutical/Medical Device/Diagnostics/Biotech

65

Consulting

15

Clinicians

2

Students

3

Other

0

Page: The Chapter Accomplishments and Contributions**Did the chapter hold virtual events during 2022?**

Yes

Describe the top 5 activities your Chapter held in 2022. Please include the date and type of activity (engagement, education and training, research, etc.)

1

Virtual seminar - societal perspective - novel Czech ISPOR chapter methodology: 80 participants: June '22

2

General meeting of Czech ISPOR chapter (engagement, education: i. OMPs - experience with new reimb. procedures and societal perspective; ii. WTP): Oct '22

3

Continually in '22: Seminars for Patient and Professional medical organization education in HTA principals (Education))

4

Launch of new Czech ISPOR task-force around WTP re-definition: Virtual seminar (Dec '22) with follow-up activities

5

Contribution in Slovakia ISPOR chapter conference: Jun '22

Research Activities

Yes

In which of the following did Chapter Members participate?

ISPOR Task Force (name of the Task Force)

not sure

ISPOR SIGs (Name of SIG)

not sure

National/Regional Research Projects (please specify)

1. guidelines for PE evaluation from the Societal perspective (<https://farmakoekonomika.cz>), 2. WTP threshold: bringing the methodology how to potentially re-define the value, based on additional value of intervention/ unmet medical/ patients need

Health Policy Activities

1. guidelines for PE evaluation from the Societal perspective (<https://farmakoekonomika.cz>), paper ready in Czech - ENG version/ publication under development
2. WTP threshold: bringing the methodology how to potentially re-define the value, based on additional value of intervention/ unmet medical/ patients need - project ongoing

Contribution to ISPOR Publications

Manuscripts in other, also non-ISPOR publishers

List Chapter member contributions to ISPOR events in 2022.

Presented Posters

Cost-Effectiveness Analysis of 4% Fluorouracil for the Treatment of Actinic Keratosis in the Czech Republic; EE440,2022-11, ISPOR Europe 2022, Vienna, Austria Novel Approach to Decision Making for Orphan Drugs; HTA74,2022-11, ISPOR Europe 2022, Vienna, Austria Time in Remission as an Alternative Outcome Measure for Ankylosing Spondylitis: A 4-Year Prospective Study of 1900 Users of Anti-TNF; CO148,2022-11, ISPOR Europe 2022, Vienna, Austria Indirect Treatment Comparison and Cost-Minimization Analysis of Riociguat Versus Selexipag in Patients With Pulmonary Arterial Hypertension; EE295,2022-11, ISPOR Europe 2022, Vienna, Austria The Life With Cystic Fibrosis: Socioeconomic Impact of the Disease on Patients and Their Caregivers in the Czech Republic; PCR186,2022-11, ISPOR Europe 2022, Vienna, Austria Patient-Reported Symptoms Are the Sole Independent Predictor of the Societal Burden Associated With Inflammatory Bowel Disease: A Cross-Sectional Study; PCR128,2022-11, ISPOR Europe 2022, Vienna, Austria Cost-Effectiveness Analysis of Entrectinib for Treatment NTRK Fusion-Positive Tumors in Czech Republic; EE242,2022-11, ISPOR Europe 2022, Vienna, Austria

Forums

ISPOR Europe 2022

Other (please describe)

ISPOR consortium meetings

Please describe your Chapter's planned activities for 2023.

Events

- WTP re-definition: - Czech ISPOR task-force with follow-up activities - workshops, events
- JCA implementation - seminars
- General meeting of Czech ISPOR chapter Autumn 2023
- contribution to Slovakia ISPOR chapter conference

Membership Engagement Opportunities in 2023

Slovakian ISPOR chapter conferences participation, CEE consortium mtgs

Collaborations

local HTA body, Ministry of Health, Payers, Patients organizations

New Research/Publication/Education Initiatives

2. WTP threshold: bringing the methodology how to potentially re-define the value, based on additional value of intervention/ unmet medical/ patients need - white paper (summer '23) and new methodology creation (YE '23)

How has your Chapter contributed to improving HEOR in your country?

- Local guidelines for HE studies development
- publication activity in HEOR topics
- Societal perspectives and indirect costs new methodology development
- WTP methodology task force lead
- PAG education

Page: The Chapter Scientific Content Activities

Describe Chapter regional patient engagement activities in the past year.

Collaboration with patient engagement organizations (for example: Rare Disease Patient Organisation (EURODIS), EUPATI)

Local Rare Disease Patient Organization: ČAVO
and others PAG

Events or conferences with patient engagement focus

Education of patients organizations

Publications

n.a.

Training

Education of patients organizations

Other (please specify)

Describe Chapter HTA-focused activities in the past year.

Collaboration with regional and national HTA bodies

- Local HTA body - SUKL
- MOH

Events or conferences with HTA focus

Virtual seminars, conferences on new methodology of societal perspective (Jun '22)
Major local Chapter mtg, around the rmb. law for orphans, WTP (Oct '22)

Development of PE guidelines

new methodology of societal perspective; up to now only in Czech:
<https://farmakoekonomika.cz/zakladni-principy-celospolecenskehodnoceni-zdravotnickychtechnologii-v-podminkach-cr/>

ENG version/ transcript in development

Publications

Novel Approach to Decision Making for Orphan Drugs; HTA74,2022-11, ISPOR Europe 2022, Vienna, Austria

Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study

Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora Velackova, Barbora Pilnackova & Tomas Dolezal: Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study, Expert Review of Gastroenterology & Hepatology (2022)

Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension

Ornstová E, Tužil J, Chadimová K, Mičoch T & Doležal T: Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension, Expert Review of Pharmacoeconomics & Outcomes Research (2022)

Other (please specify)**Research Groups**

No

Describe Chapter RWE-focused activities in the past year.

Conferences/Events

selected publications - as mentioned below

Trainings

selected publications - as mentioned below

Publications

Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study

Barbora Decker, Jan Tuzil, Milan Lukas, Karin Cerna, Martin Bortlik, Barbora

Velackova, Barbora Pilnackova & Tomas Dolezal: Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study, Expert Review of Gastroenterology & Hepatology (2022)

Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide

Štrosová D, Tužil J, Velacková Turková B, Filková Pilnáčková B, Lžičarová de Souza L, Doležalová H, Rašková M, Dufek M, Doležal T: Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide, Pharmaceuticals 2022, Volume 15, Issue 10, 1248

Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-world evidence from the Czech Republic

Turková B, Tužil J, Pilnáčková B, Doležalová H, Štrosová D, Petrů V, Seberová E & Doležal: Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-world evidence from the Czech Republic, Immunotherapy , Future Medicine (2022)

Other (please specify)

Describe Chapter activities in the past year.

Conferences/Events

n.a.

Trainings

n.a.

Publications

n.a.

Other (please specify)

Page: The Chapter Partnerships and Collaborations

Students & New Professionals

Yes

Please Describe

Students are newly accepted in the local chapter, and are included in the research activities

Please indicate Chapter affiliations other than ISPOR

- Faculty of Pharmacy, Charles University in Prague, Czech Republic
- Institute of Health Economics and Technology Assessment, Czech Republic
- Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Department of Medical Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic
- SUKL (State Institute of Drug Control)

Did the Chapter have any agreements of sponsorship arrangements with any for-profit companies, governments, health authorities, or associations in the past year?

No